73.2 F
San Fernando
Thursday, Feb 29, 2024
Array

MannKind Sees Prescriptions Bump Up

Prescriptions for Valencia biotech MannKind Corp.’s lead product reached over 380, according to contributor Spencer Osborne at Seeking Alpha, a stock market insight website. This was the highest number of prescriptions written for the Mannkind’s inhalable insulin Afrezza, since the company launched its internal marketing department about a year ago. Prescription numbers for Afrezza at its peak was around 600, when MannKind was in a marketing partnership with Sanofi, a French pharmaceutical company. However, since Sanofi pulled out of the partnership about a year and a half ago, the script numbers have been in the low 300’s. MannKind (MKND) shares jumped early Friday but then closed down 2 cents, or less than 2 percent, to $1.50 on the Nasdaq.

Featured Articles

Related Articles